Trial Profile
A proof-of-concept clinical trial of IDRA-008.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs IDRA 008 (Primary)
- Indications Liver disorders
- Focus Adverse reactions; Proof of concept
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 06 Nov 2017 According to an Idera Pharmaceuticals Inc. media release, this trial is expected to initiate in the first half of 2018.
- 11 May 2017 New trial record